ABA Autism denied as experimental or investigational by Humana?

Humana's specific coverage criteria for aba autism are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied ABA Therapy as "Experimental" — and Why You Can Appeal

Labeling ABA therapy "experimental" or "investigational" for Autism Spectrum Disorder is one of the most legally and clinically vulnerable denial positions an insurer can take. ABA has decades of peer-reviewed research supporting its use in ASD, and is endorsed as an evidence-based practice by major professional and governmental bodies including the American Academy of Pediatrics, the American Psychological Association, the U.S. Surgeon General, and the Centers for Medicare and Medicaid Services. It is covered under federal Medicaid mandates in many states, and state autism insurance mandates in the majority of U.S. states explicitly require ABA coverage.

This denial is also a potential MHPAEA violation: if Humana covers other rehabilitative therapies — such as physical or occupational therapy — without an "experimental" review, applying that standard only to a behavioral health service is a non-quantitative treatment limitation disparity.

## Federal Appeal Framework

• ACA §2719 / External Review: You have approximately 180 days from denial to request independent external review. An independent reviewer will assess whether ABA meets accepted standards of evidence — a fight the insurer regularly loses. Expedited review is available when health could be seriously jeopardized.
• ERISA §503: The plan must provide a written explanation citing the specific evidence standard used to classify ABA as experimental and the basis for that classification.
• MHPAEA: Request Humana's written NQTL analysis comparing how it applies experimental standards to behavioral versus medical/surgical benefits.
• State autism mandate: Verify whether your state's autism insurance mandate independently requires coverage and whether it overrides Humana's policy.

## Documentation to Gather

• Medical-necessity and evidence letter: The treating physician or BCBA should cite the professional society endorsements, evidence base, and guideline support for ABA as a standard-of-care treatment for ASD.
• Diagnosis confirmation: Licensed clinician's ASD diagnosis.
• Treatment plan and functional assessments: Current severity documentation and individualized treatment goals.
• Humana's coverage policy: Identify the specific language used to classify ABA as experimental and the evidence threshold invoked.

## Criteria-Mapping Structure

For each element of Humana's experimental/investigational definition, provide the evidence-based counter: professional society endorsements, guideline organization recognition, and established use in clinical practice. Challenge Humana to identify a comparable medical rehabilitation therapy that meets a stricter evidentiary standard under the same plan.